Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.
- Citation:
- J Thorac Oncol vol 7 (5) 919-22
- Year:
- 2012
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 1
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-25224
- Corr. Author:
- Authors:
- Thanyanan Reungwetwattana Julian R Molina Sumithra J Mandrekar Katie Allen-Ziegler Kendrith M Rowland Nicholas F Reuter Ronnie F Luyun Grace K Dy Randolph S Marks Steven E Schild James R Jett Alex A Adjei
- Networks:
- Study
- NCCTG-N0323
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunoenzyme Techniques, Lung Neoplasms, Male, Middle Aged, PTEN Phosphohydrolase, Phosphorylation, Prognosis, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Ribosomal Protein S6 Kinases, 70-kDa, Sirolimus, Tumor Cells, Cultured